CONCORDBIO
Concord Biotech Limited (CONCORDBIO) Stock Analysis
Concord Biotech Limited is an Indian biotechnology company making fermentation-based APIs. It supplies immunosuppressants and specialty actives to global pharma customers. Export sales and capacity expansion from India support its growth profile. The company is listed on Indian stock exchanges and operates from India.
Healthcare › Biotechnology
₹1,361.40
-0.92% 1W | -15.20% 52W
Market Cap
14.2k CR
P/E Ratio
46.9
52W High
₹1627
52W Low
₹987
Div. Yield
0.57%
Beta
0.4
50 DMA
₹1457.9
200 DMA
₹1261.4
Profit Margin
24.8%
Inst. Own.
15%
✅ BOUNCE FROM SUPPORT
✅ BOUNCE FROM SUPPORT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 195 | 262 | 241 | 319 | 216 | 310 | 244 | 430 | 204 | 247 | 278 | 326 | 257 |
| Expenses | 123 | 147 | 135 | 187 | 135 | 176 | 146 | 241 | 143 | 159 | 179 | 208 | 175 |
| Operating Profit | 72 | 116 | 106 | 132 | 81 | 134 | 98 | 189 | 61 | 88 | 98 | 118 | 82 |
| OPM % | 37% | 44% | 44% | 41% | 38% | 43% | 40% | 44% | 30% | 36% | 35% | 36% | 32% |
| Other Income | 13 | 8 | 11 | 11 | 12 | 10 | 17 | 9 | 15 | 16 | 7 | 15 | 14 |
| Interest | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 13 | 13 | 14 | 14 | 13 | 13 | 13 | 15 | 18 | 18 | 19 | 20 | 18 |
| Profit before tax | 71 | 110 | 103 | 129 | 80 | 130 | 101 | 184 | 59 | 86 | 86 | 114 | 78 |
| Tax % | 23% | 26% | 25% | 26% | 25% | 27% | 25% | 24% | 25% | 26% | 26% | 22% | 26% |
| Net Profit | 54 | 81 | 78 | 95 | 60 | 96 | 76 | 140 | 44 | 63 | 64 | 88 | 58 |
| EPS in Rs | 5.21 | 7.74 | 7.41 | 9.08 | 5.70 | 9.15 | 7.26 | 13.42 | 4.21 | 6.08 | 6.16 | 8.49 | 5.59 |
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 512 | 616 | 713 | 853 | 1,017 | 1,200 | 1,055 | 1,108 |
| Expenses | 308 | 289 | 443 | 509 | 585 | 694 | 687 | 721 |
| Operating Profit | 205 | 327 | 270 | 344 | 432 | 506 | 368 | 388 |
| OPM % | 40% | 53% | 38% | 40% | 42% | 42% | 35% | 35% |
| Other Income | 32 | 14 | 23 | 37 | 37 | 44 | 52 | 52 |
| Interest | 1 | 1 | 6 | 5 | 3 | 1 | 1 | 0 |
| Depreciation | 21 | 28 | 50 | 54 | 54 | 54 | 74 | 75 |
| Profit before tax | 214 | 313 | 238 | 322 | 413 | 495 | 345 | 364 |
| Tax % | 21% | 25% | 26% | 25% | 25% | 25% | 25% | |
| Net Profit | 169 | 235 | 175 | 240 | 308 | 372 | 259 | 273 |
| EPS in Rs | 177.81 | 247.44 | 183.93 | 22.95 | 29.45 | 35.52 | 24.94 | 26.32 |
| Dividend Payout % | 22% | -0% | 3% | 30% | 30% | 25% | 30% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 7.0% | 11.0% | – |
| Profit CAGR | 0.0% | 1.0% | – |
Shareholding Pattern
Promoters44.08%
FIIs9.10%
DIIs8.85%
Public37.94%
Promoters44.08%
FIIs8.03%
DIIs9.55%
Public38.32%
Promoters44.08%
FIIs7.58%
DIIs9.58%
Public38.75%
Promoters44.08%
FIIs7.79%
DIIs9.22%
Public38.90%
Promoters44.08%
FIIs7.53%
DIIs9.37%
Public39.04%
Promoters44.08%
FIIs6.49%
DIIs8.41%
Public41.03%
Promoters44.08%
FIIs9.35%
DIIs9.16%
Public37.41%
Promoters44.08%
FIIs7.79%
DIIs9.22%
Public38.90%
Promoters44.08%
FIIs7.53%
DIIs9.37%
Public39.04%
CONCORDBIO
Holdings Analysis
Key strengths & risk signals
58
Overall
47
Fundamental
70
Technical
Risks (4)
OVERVALUED! PEG of 16.75 means expensive relative to growth rate.
RECOVERY MODE! Current price (1361.4) above 200-day but below 50-day.
WEAK YEAR! Stock declined 15.2% in the last year.
WEAK MOMENTUM! Limited price growth - -0.9% (1 week), -7.0% (1 month), 4.3% (3 months).
Strengths (4)
EXCELLENT EFFICIENCY! 24.8% profit margin - company keeps strong profits.
BULLISH TREND! 50-day average (1457.9) is above 200-day average (1261.4) - positive signal.
LOW VOLATILITY! Beta of 0.40 - stable stock, less market risk.
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 179,938 vs down days: 127,383. Ratio: 1.41x
Fundamental & Technical Analysis
58Overall
47Fundamental
70Technical
Fundamental Breakdown
Growth Quality
13/30
Revenue CAGR: 8.0% (MODERATE, 8/15). Profit CAGR: 2.8% (SLOW, 5/15).
Profit Margin
8/10
EXCELLENT EFFICIENCY! 24.8% profit margin - company keeps strong profits.
PEG Valuation
0/10
OVERVALUED! PEG of 16.75 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.57% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
5/20
TOO MUCH PUBLIC HOLDING! 40.5% public ownership - higher volatility risk.
Stability Index
8/10
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (1457.9) is above 200-day average (1261.4) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (1361.4) above 200-day but below 50-day.
Trend Pattern
16/20
TESTING SUPPORT! Stock is at key support level.
52W Performance
2/10
WEAK YEAR! Stock declined 15.2% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 179,938 vs down days: 127,383. Ratio: 1.41x
RSI
3/5
NEUTRAL! RSI at 42.3 - balanced momentum.
52W Range
3/5
MID RANGE! Trading at 58.5% of 52W range - neutral zone.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -0.9% (1 week), -7.0% (1 month), 4.3% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.40 - stable stock, less market risk.
CONCORDBIO
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-07 | Concall PDF | |
| Q4FY262026-06-05 | Concall PDF | |
| Q3FY262026-02-18 | Concall PDF | |
| Q2FY262025-11-19 | Concall PDF |
Peer Comparison
Healthcare · Biotechnology · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CONCORDBIO | ₹1,361.40 | 46.9 | 24.8% | 8.0% | 2.8% | -15.2% | 58 | BOUNCE FROM SUPPORT | +30.8% | -35.0% | +26.2% | -21.0% |
| ONESOURCE | ₹1,461.30 | – | -3.1% | 232.4% | – | -18.3% | 44 | BREAKDOWN | -12,600.0% | +443.5% | +37.2% | +4.9% |
| BLUEJET | ₹514.60 | 38 | 26.5% | 9.4% | 15.7% | -17.2% | 73 | BOUNCE FROM SUPPORT | -14.1% | +21.8% | -17.4% | +24.9% |
| SUPRIYA | ₹847.60 | 34.4 | 22.7% | 21.2% | 32.5% | +23.4% | 83 | BOUNCE FROM SUPPORT | -31.0% | -67.7% | +30.7% | -31.4% |
| ZOTA | ₹1,324.10 | – | -17.0% | 56.7% | – | -7.9% | 57 | CONSOLIDATING UP | +204.9% | +207.0% | +67.6% | +6.4% |
| DCAL | ₹149.70 | 145.3 | 0.6% | 9.0% | 21.0% | -50.1% | 55 | BOUNCE FROM SUPPORT | -347.9% | -367.3% | -4.2% | -20.4% |
| PANACEABIO | ₹345.20 | – | -1.1% | 10.1% | – | -17.9% | 49 | BOUNCE FROM SUPPORT | -42.5% | +360.0% | +19.7% | +19.7% |
| HALEOSLABS | ₹1,563.70 | 29.9 | 4.9% | 0.3% | 14.7% | +41.6% | 69 | BREAKOUT | -38.1% | +550.0% | -11.6% | -2.9% |
Data from TradeAlone · Updated daily
